Compare · AEMD vs RMD
AEMD vs RMD
Side-by-side comparison of Aethlon Medical Inc. (AEMD) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEMD and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.02B, about 5903.9x AEMD ($4.7M).
- Over the past year, AEMD is down 99.2% and RMD is down 23.1% - RMD leads by 76.1 points.
- RMD has been more active in the news (6 items in the past 4 weeks vs 4 for AEMD).
- RMD has more recent analyst coverage (25 ratings vs 2 for AEMD).
- Company
- Aethlon Medical Inc.
- ResMed Inc.
- Price
- $2.03+2.53%
- $193.21-1.43%
- Market cap
- $4.7M
- $28.02B
- 1M return
- -10.57%
- -6.57%
- 1Y return
- -99.20%
- -23.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 6
- Recent ratings
- 2
- 25
Aethlon Medical Inc.
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest AEMD
- Aethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Aethlon Medical Inc.
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
- Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
- SEC Form 4 filed by Gikakis Nicolas
- SEC Form 4 filed by Broenniman Edward G
- SEC Form 4 filed by Rossetti Angela
- SEC Form 4 filed by Shah Chetan
- SEC Form 4 filed by Shah Chetan
- SEC Form 4 filed by Gikakis Nicolas
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.